Huawei Expands AI Collaboration with Pharmaceutical Companies
Chinese technology company Huawei is planning to expand its artificial intelligence (AI) partnerships with local pharmaceutical firms into drug development and clinical practice, according to William Zhang, president of Huawei's healthcare business unit. This move reflects the company’s ambition to enter the rapidly growing market for AI-driven drug discovery, where pharma companies are increasingly adopting modeling tools and automated labs to accelerate research timelines. Huawei currently has collaborations in hospital-based clinical practices and is exploring more opportunities with domestic pharmaceutical firms. The firm offers AI tools for screening potential drug compounds alongside its Ascend and Kunpeng chips. In May 2026, Huawei announced a project involving Guangzhou Pharmaceutical Holdings as the first production validation of independently developed AI models adapted to its technologies. The expansion aligns with broader industry trends where companies like Nvidia are also forming partnerships in this space.
Tickers: $NVDA
Topics: AI drug development Huawei pharmaceuticals